Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 4Gynecologic 3Thoracic 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × belinostat × Dermatologic × Clear all
NCT00274651 2015-07-28

PXD101-CLN-6

Valerio Therapeutics

Phase 2 Terminated
53 enrolled 12 charts
DermatologicLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡